western blot

PTZ-343 是一种鲁米诺的强效发光增强剂 (enhancer)。它极大的增强了过氧化物酶催化的鲁米诺化学发光氧化反应 (>80%) 的光输出。

YD-3作为一种PAR4拮抗剂，能显著抑制由凝血酶引起的洗涤兔血小板聚集（IC(50)=28.3 microM）。此外，YD-3抑制凝血酶诱导的血管平滑肌细胞增殖，并能减轻气球伤害后的内膜增厚。通过Ras-和ERK1/2介导的信号传导途径，YD-3抑制凝血酶诱导的VSMC生长。在使用Western blot分析时，YD-3主要抑制由凝血酶引起的血管内皮生长因子受体2（Flk-1）表达，而不影响细胞外信号调节激酶1/2的磷酸化。YD-3在阐明由凝血酶诱导的血管生成病理生理学中可能具有潜在价值。

RWJ-56110 dihydrochloride is a potent, selective, peptide-mimetic inhibitor of PAR-1 activation and internalization (binding IC50=0.44 uM) and shows no effect on PAR-2, PAR-3, or PAR-4. RWJ-56110 dihydrochloride inhibits the aggregation of human platelets induced by both SFLLRN-NH2 (IC50=0.16 μM) and thrombin (IC50=0.34 μM), quite selective relative to U46619 . RWJ-56110 dihydrochloride blocks angiogenesis and blocks the formation of new vessels in vivo. RWJ-56110 dihydrochloride induces cell apoptosis[1][2]. Proteinase-activated receptors (PARs) are a family of G protein-coupled receptors activated by the proteolytic cleavage of their N-terminal extracellular domain, exposing a new amino terminal sequence that functions as a tethered ligand to activate the receptors.RWJ56110 inhibits the aggregation of human platelets induced by both SFLLRN-NH2 (IC50=0.16 μM) and thrombin (IC50=0.34 μM) while being quite selective relative to collagen and the thromboxane mimetic U46619 [1].RWJ-56110 dihydrochloride is fully inhibits thrombin-induced RASMC proliferation with an IC50 value of 3.5 μM. RWJ-56110 dihydrochloride shows blockade of thrombin's action with RASMC calcium mobilization (IC50=0.12 μM), as well as with HMVEC (IC50=0.13 μM) and HASMC calcium mobilization (IC50=0.17 μM)[1].RWJ56110 (0.1-10 μM; 24-96 hours) inhibits endothelial cell growth dose-dependently, with half-maximal inhibitory concentration of RWJ56110 is approximately 10 μM[2].RWJ56110 (0.1-10 μM; 6 hours) inhibits DNA synthesis of endothelial cells in a thymidine incorporation assays. Endothelial cells are in fast-growing state (50-60% confluence), RWJ56110 inhibits cell DNA synthesis in a dose-dependent manner, but when cells that are in the quiescent state (100% confluent), the inhibitory effect of PAR-1 antagonists is much less pronounced[2].RWJ56110 (0.1-10 μM; pretreatment for 15 min) inhibits thrombin-induced Erk1/2 activation in a concentration-dependent manner. However, when endothelial cells are stimulated by FBS (final concentration 4%), it reduces partially the activated levels of Erk1/2[2].RWJ56110 (30 μM; 24 hours) has an inhibitory effect on endothelial cell cycle progression. It reduces the percentage of cells in the S phase, while alterations in the percentages of G1 and G2/M cells are less pronounced[2]. Western Blot Analysis[2] Cell Line: Endothelial cells [1]. Andrade-Gordon, et al.Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor. oc Natl Acad Sci U S A. 1999 Oct 26;96(22):12257-62. [2]. Panagiota Zania, et al. Blockade of angiogenesis by small molecule antagonists to protease-activated receptor-1: association with endothelial cell growth suppression and induction of apoptosis. J Pharmacol Exp Ther. 2006 Jul;318(1):246-54.

MHY219 is a novel HDAC inhibitor. MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells. MHY219 was shown to enhance the cytotoxicity on DU145 cells (IC50, 0.36 μM) when compared with LNCaP (IC50, 0.97 μM) and PC3 cells (IC50, 5.12 μM). MHY219 showed a potent inhibition of total HDAC activity when compared with SAHA. MHY219 increased histone H3 hyperacetylation and reduced the expression of class I HDACs (1, 2 and 3) in prostate cancer cells. MHY219 effectively increased the sub-G1 fraction of cells through p21 and p27 dependent pathways in DU145 cells. MHY219 significantly induced a G2/M phase arrest in DU145 and PC3 cells and arrested the cell cycle at G0/G1 phase in LNCaP cells. Furthermore, MHY219 effectively increased apoptosis in DU145 and LNCaP cells, but not PC3 cells, according to Annexin V/PI staining and Western blot analysis. These results indicate that MHY219 is a potent HDAC inhibitor that targets regulating mu......

3X HA Tag（Triple-HA Tag）是一种生物活性肽，由三个重复的 HA 标签（YPYDVPDYA）通过肽键连接而成，主要用于蛋白质和肽的检测以及促进目标蛋白质的功能分析。3X HA Tag 可以被抗 HA 标签的抗体特异性识别和结合，广泛应用于 Western blot、免疫荧光、免疫沉淀等实验技术。

NDT-19795 是一种有效的小分子 NLRP3 炎性小体抑制剂，在基于 PBMC 的实验中 IC50 为 66 nM，在 western blot 分析中 IC50 为 4.7 μM。该化合物是 NT-0796 在细胞内代谢生成的羧酸型活性代谢物，支持其在神经炎症及神经系统疾病机制研究中的应用。

Matairesinoside 是从日本安息香 (Styrax japonica S. et Z) 树皮中分离的木脂素，具有抗菌、抗氧化特性，并能作为病毒与细胞融合抑制剂。研究显示，Matairesinoside 是 ANO1 的强效抑制剂，该靶点参与肺癌进展。分子模拟及定点突变实验证实其靶向作用。Matairesinoside 显著抑制肺癌细胞增殖、迁移及侵袭，并诱导凋亡。

AMPSO 是一种碱性转移缓冲液，可将强碱性蛋白质从凝胶转移至硝酸纤维素，而不影响其他蛋白质的转移效率。AMPSO 适用于 Western Blot 分析、PCR 扩增及多种其他应用。

10× TBSTw（TBS with Tween-20）为10倍浓缩的Tris缓冲盐溶液（含Tween-20），即在TBS基础上加入非离子型表面活性剂Tween-20。主要组分包括Tris、Tris-HCl、NaCl和Tween-20，其中Tris/Tris-HCl提供稳定的pH缓冲体系，NaCl维持离子强度，Tween-20作为去污剂降低表面张力、增强洗涤能力并减少非特异性结合。10× TBSTw（TBS with Tween-20）是免疫学实验中最常用的洗涤缓冲液之一，主要用于免疫印迹（Western Blot）、抗体孵育与洗涤、封闭液配置和其他免疫学实验。本产品为10×浓缩液，使用前须用蒸馏水或去离子水稀释至1×工作浓度。

1× TBSTw（TBS with Tween-20）为Tris缓冲盐溶液（含Tween-20），即在TBS基础上加入非离子型表面活性剂Tween-20。主要组分包括Tris、Tris-HCl、NaCl和Tween-20，其中Tris/Tris-HCl提供稳定的pH缓冲体系，NaCl维持离子强度，Tween-20作为去污剂降低表面张力、增强洗涤能力并减少非特异性结合。1× TBSTw（TBS with Tween-20）是免疫学实验中最常用的洗涤缓冲液之一，主要用于免疫印迹（Western Blot）、抗体孵育与洗涤、封闭液配置和其他免疫学实验。